Patent · US Active

Anti-PD-L1 antibodies and use thereof

US12054548B2 · kind B2 · utility

0Cited by

0References

11Claims

0Family size

Assignee

Adagene Inc. · KY

Inventors

Peizhi Luo · Arcadia, US
Fangyong Du · 安丰镇, CN
Guizhong LIU · Suzhou, CN
Yan Li · Tianjin, CN

Key dates

Filing date	Mar 29, 2019
Grant date	Aug 6, 2024
Priority date	—
Expiry date	Oct 30, 2041

Classification

Technology area (CPC G)Physics
CPC primaryG01N2333/70596
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure provides antibodies that bind to the T-cell co-inhibitor ligand programmed death-ligand1 (PD-L1) protein, and methods of use. In various embodiments of the disclosure, the antibodies are fully human antibodies that bind to PD-L1. In certain embodiments, the present disclosure provides multi-specific antigen-binding molecules comprising a first binding specificity that binds to PD-L1 and a second binding specificity that binds to a tumor cell antigen, an infected cell-specific antigen, or a T-cell co-inhibitor. In some embodiments, the antibodies of the disclosure are useful for inhibiting or neutralizing PD-L1 activity, thus providing a means of treating a disease or disorder such as cancer or viral infection.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.